Clinical Implications of the Associations Between Intestinal Microbiome and Colorectal Cancer Progression

References

• Li Q, Gao Z, Wang H, et al. Intestinal immunomodulatory cells (T Lymphocytes): a bridge between gut microbiota and diabetes. Mediators Inflamm. 2018;2018:9830939. doi:10.1155/2018/983093929713241
   PubMed Web of Science ®Google Scholar
• Altamirano-Barrera A, Uribe M, Chavez-Tapia NC, Nuno-Lambarri N. The role of the gut microbiota in the pathology and prevention of liver disease. J Nutr Biochem. 2018;60:1–8. doi:10.1016/j.jnutbio.2018.03.00629653359
   PubMed Web of Science ®Google Scholar
• Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol. 2018;14(7):442–456. doi:10.1038/s41581-018-0018-229760448
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800–812. doi:10.1038/nrc361024132111
   PubMed Web of Science ®Google Scholar
• Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21(4):504–516. doi:10.1016/j.ccr.2012.02.00722516259
   PubMed Web of Science ®Google Scholar
• Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. Br J Cancer. 2016;115(3):273–280. doi:10.1038/bjc.2016.18927380134
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–976. doi:10.1126/science.124053724264990
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970. doi:10.1126/science.124052724264989
   PubMed Web of Science ®Google Scholar
• Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084. doi:10.1126/science.aad132926541610
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6:8727. doi:10.1038/ncomms972726515465
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Wiseman M. The Second World Cancer Research Fund/American Institute for Cancer Research Expert Report. food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008;67(3):253–256. doi:10.1017/S002966510800712X18452640
   PubMed Web of Science ®Google Scholar
• Han S, Gao J, Zhou Q, Liu S, Wen C, Yang X. Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review. Cancer Manag Res. 2018;10:199–206. doi:10.2147/CMAR.S15348229440929
   PubMed Web of Science ®Google Scholar
• Dejea CM, Fathi P, Craig JM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359(6375):592–597. doi:10.1126/science.aah364829420293
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–582. doi:10.1038/nrmicro281922728587
   PubMed Web of Science ®Google Scholar
• Wong SH, Zhao L, Zhang X, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 2017;153(6):1621–1633 e1626. doi:10.1053/j.gastro.2017.08.02228823860
   PubMed Web of Science ®Google Scholar
• Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20. doi:10.3389/fmicb.2015.0002025699023
   PubMed Web of Science ®Google Scholar
• Baxter NT, Ruffin M, Rogers MA, Schloss PD. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med. 2016;8(1):37. doi:10.1186/s13073-016-0290-327056827
   PubMedGoogle Scholar
• Eklof V, Lofgren-Burstrom A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int J Cancer. 2017;141(12):2528–2536. doi:10.1002/ijc.3101128833079
   PubMed Web of Science ®Google Scholar
• Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 2017;23(8):2061–2070. doi:10.1158/1078-0432.CCR-16-159927697996
   PubMed Web of Science ®Google Scholar
• Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105(24):1907–1911. doi:10.1093/jnci/djt30024316595
   PubMedGoogle Scholar
• Zeller G, Tap J, Voigt AY, et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol. 2014;10:766. doi:10.15252/msb.2014564525432777
   PubMed Web of Science ®Google Scholar
• Wang X, Ye T, Chen WJ, et al. Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice. World J Gastroenterol. 2017;23(46):8128–8139. doi:10.3748/wjg.v23.i46.812829290650
   PubMed Web of Science ®Google Scholar
• Warren RL, Freeman DJ, Pleasance S, et al. Co-occurrence of anaerobic bacteria in colorectal carcinomas. Microbiome. 2013;1(1):16. doi:10.1186/2049-2618-1-1624450771
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70–78. doi:10.1136/gutjnl-2015-30980026408641
   PubMed Web of Science ®Google Scholar
• Dai Z, Coker OO, Nakatsu G, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018;6(1):70. doi:10.1186/s40168-018-0451-229642940
   PubMed Web of Science ®Google Scholar
• Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology. 2017;152(6):1419–1433 e1415. doi:10.1053/j.gastro.2017.01.00928126350
   PubMed Web of Science ®Google Scholar
• Zhou Y, He H, Xu H, et al. Association of oncogenic bacteria with colorectal cancer in South China. Oncotarget. 2016;7(49):80794–80802. doi:10.18632/oncotarget.1309427821805
   PubMedGoogle Scholar
• Konstantinov SR, Kuipers EJ, Peppelenbosch MP. Functional genomic analyses of the gut microbiota for CRC screening. Nat Rev Gastroenterol Hepatol. 2013;10(12):741–745. doi:10.1038/nrgastro.2013.17824042452
   PubMed Web of Science ®Google Scholar
• Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1298–1303. doi:10.1111/j.1440-1746.2008.05490.x18624900
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22(2):299–306. doi:10.1101/gr.126516.11122009989
   PubMed Web of Science ®Google Scholar
• Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science. 2017;358(6369):1443–1448. doi:10.1126/science.aal524029170280
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–1980. doi:10.1136/gutjnl-2015-31010126311717
   PubMed Web of Science ®Google Scholar
• Mima K, Cao Y, Chan AT, et al. Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location. Clin Transl Gastroenterol. 2016;7(11):e200. doi:10.1038/ctg.2016.5327811909
   PubMedGoogle Scholar
• Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355. doi:10.1016/j.immuni.2015.01.01025680274
   PubMed Web of Science ®Google Scholar
• Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappaB, and up-regulating expression of MicroRNA-21. Gastroenterology. 2017;152(4):851–866 e824. doi:10.1053/j.gastro.2016.11.01827876571
   PubMed Web of Science ®Google Scholar
• Viljoen KS, Dakshinamurthy A, Goldberg P, Blackburn JM, McDowell A. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer. PLoS One. 2015;10(3):e0119462. doi:10.1371/journal.pone.011946225751261
   PubMed Web of Science ®Google Scholar
• Boleij A, Hechenbleikner EM, Goodwin AC, et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015;60(2):208–215. doi:10.1093/cid/ciu78725305284
   PubMed Web of Science ®Google Scholar
• Chung L, Thiele Orberg E, Geis AL, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 2018;23(2):203–214 e205. doi:10.1016/j.chom.2018.01.00729398651
   PubMed Web of Science ®Google Scholar
• Thiele Orberg E, Fan H, Tam AJ, et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 2017;10(2):421–433. doi:10.1038/mi.2016.5327301879
   PubMed Web of Science ®Google Scholar
• Veziant J, Gagniere J, Jouberton E, et al. Association of colorectal cancer with pathogenic Escherichia coli: focus on mechanisms using optical imaging. World J Clin Oncol. 2016;7(3):293–301. doi:10.5306/wjco.v7.i3.29327298769
   PubMedGoogle Scholar
• Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6:6528. doi:10.1038/ncomms752825758642
   PubMed Web of Science ®Google Scholar
• Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients’ survival? A pilot study on relevant mechanism. Oncotarget. 2016;7(29):46158–46172. doi:10.18632/oncotarget.1006427323816
   PubMedGoogle Scholar
• Bonnet M, Buc E, Sauvanet P, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014;20(4):859–867. doi:10.1158/1078-0432.CCR-13-134324334760
   PubMed Web of Science ®Google Scholar
• Yoon H, Kim N, Park JH, et al. Comparisons of gut microbiota among healthy control, patients with conventional adenoma, sessile serrated adenoma, and colorectal cancer. J Cancer Prev. 2017;22(2):108–114. doi:10.15430/JCP.2017.22.2.10828698865
   PubMedGoogle Scholar
• Kinross J, Mirnezami R, Alexander J, et al. A prospective analysis of mucosal microbiome-metabonome interactions in colorectal cancer using a combined MAS 1HNMR and metataxonomic strategy. Sci Rep. 2017;7(1):8979. doi:10.1038/s41598-017-08150-328827587
   PubMedGoogle Scholar
• Cremonesi E, Governa V, Garzon JFG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018;67(11):1984–1994. doi:10.1136/gutjnl-2016-31349829437871
   PubMed Web of Science ®Google Scholar
• Yan X, Liu L, Li H, Qin H, Sun Z. Clinical significance of Fusobacterium nucleatum, epithelial-mesenchymal transition, and cancer stem cell markers in stage III/IV colorectal cancer patients. Onco Targets Ther. 2017;10:5031–5046. doi:10.2147/OTT.S14594929081665
   PubMed Web of Science ®Google Scholar
• Lennard KS, Goosen RW, Blackburn JM. Bacterially-associated transcriptional remodeling in a distinct genomic subtype of colorectal cancer provides a plausible molecular basis for disease development. PLoS One. 2016;11(11):e0166282. doi:10.1371/journal.pone.016628227846243
   PubMed Web of Science ®Google Scholar
• Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77–87 e72. doi:10.1053/j.gastro.2014.09.03825280443
   PubMed Web of Science ®Google Scholar
• Seppala TT, Bohm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015;112(12):1966–1975. doi:10.1038/bjc.2015.16025973534
   PubMed Web of Science ®Google Scholar
• Manceau G, Marisa L, Boige V, et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Med. 2015;4(3):371–382. doi:10.1002/cam4.37025641861
   PubMed Web of Science ®Google Scholar
• Flanagan L, Schmid J, Ebert M, et al. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis. 2014;33(8):1381–1390. doi:10.1007/s10096-014-2081-324599709
   PubMed Web of Science ®Google Scholar